Radocha Jakub, van de Donk Niels W C J, Weisel Katja
4th Department of Internal Medicine-Hematology, Faculty of Medicine in Hradec Králové, University Hospital Hradec Kralove, Charles University, 50005 Hradec Kralove, Czech Republic.
Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.
Cancers (Basel). 2021 Mar 29;13(7):1571. doi: 10.3390/cancers13071571.
Multiple myeloma is the second most common hematologic malignancy. Current treatment strategies are mainly based on immunomodulatory drugs, proteasome inhibitors or combination of both. Novel agents added to these backbone treatments represent a promising strategy in treatment of newly diagnosed as well as relapsed and refractory multiple myeloma patients. In this respect, the incorporation of monoclonal antibodies into standard-of-care regimens markedly improved prognosis of myeloma patients during the last years. More specifically, monoclonal anti-CD38 antibodies, daratumumab and isatuximab, have been implemented into treatment strategies from first-line treatment to refractory disease. In addition, the monoclonal anti-SLAM-F7 antibody elotuzumab in combination with immunomodulatory drugs has improved the clinical outcomes of patients with relapsed/refractory disease. Belantamab mafodotin is the first approved antibody drug conjugate directed against B cell maturation antigen and is currently used as a monotherapy for patients with advanced disease. This review focuses on clinical efficacy and safety of monoclonal antibodies as well as antibody drug conjugates in multiple myeloma.
多发性骨髓瘤是第二常见的血液系统恶性肿瘤。当前的治疗策略主要基于免疫调节药物、蛋白酶体抑制剂或两者联合使用。添加到这些基础治疗中的新型药物是治疗新诊断以及复发和难治性多发性骨髓瘤患者的一种有前景的策略。在这方面，将单克隆抗体纳入标准治疗方案在过去几年中显著改善了骨髓瘤患者的预后。更具体地说，单克隆抗CD38抗体达雷妥尤单抗和isatuximab已被纳入从一线治疗到难治性疾病的治疗策略中。此外，单克隆抗信号淋巴细胞激活分子家族成员7（SLAM-F7）抗体elotuzumab与免疫调节药物联合使用改善了复发/难治性疾病患者的临床结局。贝兰他单抗马福妥汀是首个获批的针对B细胞成熟抗原的抗体药物偶联物，目前用作晚期疾病患者的单药治疗。本综述重点关注单克隆抗体以及抗体药物偶联物在多发性骨髓瘤中的临床疗效和安全性。
